Clinical Trial Detail

NCT ID NCT03891953
Title Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors.
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Novartis Pharmaceuticals
Indications

lung non-small cell carcinoma

melanoma

colorectal cancer

Advanced Solid Tumor

nasopharynx carcinoma

triple-receptor negative breast cancer

Therapies

DKY709

DKY709 + Spartalizumab

Age Groups: adult senior

No variant requirements are available.